-
Mashup Score: 0Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial - 7 month(s) ago
Key Points. Acalabrutinib has a favorable benefit-risk profile, including lower incidence of cardiovascular-related toxicities, vs ibrutinib.AE burden score all
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Acalabrutinib Improves Long-Term PFS in Patients With High-Risk CLL - 10 month(s) ago
Danielle M. Brander, MD, discusses updated results from the ELEVATE-TN trial of acalabrutinib in patients with chronic lymphocytic leukemia.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Zanubrutinib Among Patients With B-Cell Malignancies Intolerant of Other BTK Inhibitors - 1 year(s) ago
Results of a phase 2 trial indicate that using zanubrutinib as a treatment for b-cell malignancies yielded safe and effective results among patients intolerant of other BTK inhibitors.
Source: HMP Global Learning NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Clinical benefit has been achieved with zanubrutinib treatment in patients B-cell malignancies who were intolerant to acalabrutinib.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Acalabrutinib Appears to Have Quicker Time to Next Therapy Than Ibrutinib in Patients With CLL - 1 year(s) ago
Patients with chronic lymphocytic leukemia on frontline acalabrutinib were more likely to switch to another therapy or intensify their treatment earlier on, compared to those on ibrutinib, according to real-world study data.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 14Frontline Chemo-Free Triplet Yields High Rates of MRD-Negative Complete Remission in MCL | ASH Clinical News | American Society of Hematology - 1 year(s) ago
Skip Nav Destination December 10, 2022 The chemotherapy-free triplet regimen of acalabrutinib, lenalidomide, and rituximab (ALR) yielded high rates of measurable residual disease (MRD)-negative complete remission (CR) when used as a…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Program Guide – ASCO Meeting Program Guide - 2 year(s) ago
AuthorsJeff Porter SharmanWillamette Valley Cancer Institute and US Oncology Research Center, Eugene, ORJeff Porter Sharman, Miklos Egyed, Wojciech Jurczak, Alan P. Skarbnik, Manali K. Kamdar, Talha Munir, Laura Fogliatto, Yair Herishanu, Versha Banerji, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Emmanuelle Ferrant, Veerendra Munugalavadla, Ting Yu, Min Hui Wang,…
Source: meetings.asco.orgCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 1
Acalabrutinib appears to be generally well tolerated, although progression-free survival was relatively poor in this cohort of patients with Richter transformation. On the basis of these findings, the use of acalabrutinib monotherapy in this setting is limited; however, further assessment of acalabrutinib as part of combination-based regimens for patients with Richter transformation is warranted.
Source: The Lancet HaematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study - 3 year(s) ago
Acalabrutinib, venetoclax, and obinutuzumab is a highly active and well tolerated frontline therapy for chronic lymphocytic leukaemia. Although the primary endpoint of this study was not met, the high proportion of patients who had undetectable MRD in the bone marrow supports further investigation of this regimen, which is being tested against acalabrutinib–venetoclax and chemoimmunotherapy in an…
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study - 3 year(s) ago
Acalabrutinib, venetoclax, and obinutuzumab is a highly active and well tolerated frontline therapy for chronic lymphocytic leukaemia. Although the primary endpoint of this study was not met, the high proportion of patients who had undetectable MRD in the bone marrow supports further investigation of this regimen, which is being tested against acalabrutinib–venetoclax and chemoimmunotherapy in an…
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Detailed safety profile of #Acalabrutinib vs #Ibrutinib in previously treated #CLL in the #ELEVATE-RR trial 👉https://t.co/Y7bNzp0oC7 @MDedgeHemOnc #RiskBenefit https://t.co/2gnp1gfK4v